WebApr 7, 2024 · Multiple myeloma (MM) is the second most common hematological malignancy; in 2024, the National Cancer Institute indicated about 34,470 new cases were diagnosed with MM, and about 12,640 deaths ... WebDec 7, 2024 · Introduction: Flow cytometry is an important tool in detecting multiple myeloma (MM), especially in cases of minimal residual disease (MRD). The reliability and stability of CD138, a marker used in many institutions on antibody panels to detect MM, has been questioned in recent studies, spurring the search for alternative markers.
Minimal Residual Disease by Flow Cytometry: Latest …
WebMay 5, 2024 · Purpose of Review Over the last decade, the development of effective treatment approaches for multiple myeloma (MM) has been associated with higher response rates and longer survival. In patients who achieve complete response, several high sensitivity techniques have been studied to assess minimal residual disease (MRD) and … WebFeb 20, 2024 · Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among these are the anti-CD38 antibodies … sibling equality
Tests to Find Multiple Myeloma - American Cancer Society
WebApr 14, 2024 · Multiple myeloma (MM) is an adult hematologic malignancy, characterized by the uncontrolled proliferation of bone marrow (BM) plasma cells (PC), that is highly … WebDec 10, 2024 · Improvements in multiple myeloma therapy have led to deeper responses that are beyond the limit of detection by historical immunohistochemistry and conventional flow cytometry in bone marrow samples. In parallel, more sensitive techniques for … WebNov 1, 2002 · Flow cytometric analysis has not been widely used as a method for residual disease analysis in multiple myeloma, but has been previously shown to be extremely … sibling effect